Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics, Inc. (AKBA) is a biopharmaceutical leader developing innovative therapies for kidney disease, including FDA-approved Auryxia® and investigational oral HIF inhibitor Vafseo™. This page provides authorized updates on clinical developments, regulatory milestones, and strategic initiatives shaping renal care.
Access Akebia's official press releases covering phase 3 trial results, regulatory submissions, and commercial partnerships with dialysis providers. Investors will find timely updates on financial performance, including earnings calls and SEC filings related to anemia treatment innovations.
Our curated news collection helps stakeholders track progress in HIF biology applications and chronic kidney disease management. Bookmark this page for verified updates on product approvals, research collaborations, and market expansion strategies directly from Akebia Therapeutics.
Akebia Therapeutics, a biopharmaceutical company focused on improving the lives of people with kidney disease, announced that its CEO, John Butler, will participate in the H.C. Wainwright 3rd Annual Kidney Virtual Conference.
The event is set for Monday, July 15, 2024, at 9:30 a.m. ET. During the conference, Butler will provide updates on the commercial launch activities for Vafseo (vadadustat) Tablets.
Interested parties can access a webcast of the presentation through the Investors section of Akebia's website for 30 days following the event. This conference is an important platform for Akebia to showcase its advancements and strategies in the kidney disease sector.
Akebia Therapeutics, a biopharmaceutical company focusing on kidney disease treatments, announced the appointment of Erik Ostrowski as Senior Vice President, Chief Financial Officer, and Chief Business Officer.
Mr. Ostrowski, an experienced biotech executive, joins Akebia from Avrobio, where he played a key role in its merger with Tectonic Therapeutic. Previously, he was instrumental in the IPO of Summit Therapeutics and served on the Board of Directors of Faron Pharmaceuticals.
CEO John P. Butler expressed confidence in Ostrowski's leadership, emphasizing the company's strong financial position as it launches Vafseo® (vadadustat) Tablets.
Ostrowski holds degrees from Babson College and the University of Chicago Booth School of Business. He expressed enthusiasm about joining Akebia, highlighting its established revenue-generating business and promising pipeline.
Akebia Therapeutics, a biopharmaceutical company focused on kidney disease, announced on June 3, 2024, that it granted stock options to four newly-hired employees. The options, amounting to 76,000 shares with an exercise price of $1.12 per share, were granted on May 31, 2024, under Nasdaq Listing Rule 5635(c)(4). The stock options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting quarterly thereafter. Each option has a 10-year term and is subject to Akebia's inducement award program and stock option agreement.
Akebia Therapeutics announced that its CEO, John Butler, will present at the Jefferies Global Healthcare Conference on June 5, 2024, at 9:00 a.m. ET. The conference will be held in New York from June 4-6, 2024. The presentation will be accessible through a webcast on Akebia's investor website for 30 days post-event.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focusing on kidney disease, announced its participation in the 2nd Annual HCW Bioconnect Investor Conference in New York on May 20, 2024. CEO John Butler will engage in a fireside chat at 3:00 p.m. ET. The presentation will be available via webcast on Akebia's investor relations website for 30 days post-conference.
Akebia Therapeutics reported financial results for the first quarter of 2024, highlighting the FDA approval of Vafseo tablets for anemia due to chronic kidney disease. The company expects significant growth in Auryxia net product revenues in 2024 and has ample cash to support operations for the next two years.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) will release its first-quarter financial results on May 9, 2024, and host a conference call to discuss the results and recent business highlights. The call is scheduled for 8:00 a.m. ET. Investors can access the call via phone or webcast.
Akebia Therapeutics, Inc. granted 10 newly-hired employees options to purchase 41,000 shares of common stock as inducements under Nasdaq Listing Rule 5635(c)(4). The exercise price is $1.26 per share, with options vesting over four years. Each option has a 10-year term and is subject to company conditions.
FAQ
What is the current stock price of Akebia Therapeut (AKBA)?
What is the market cap of Akebia Therapeut (AKBA)?
